Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. - Wikidata - wikimedia - TriplyDB

Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

http://www.wikidata.org/entity/Q36208963

about

Accelerating the development of a group A Streptococcus vaccine: an urgent public health need Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens Structure-Informed Design of an Enzymatically Inactive Vaccine Component for Group A Streptococcus Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model A molecular trigger for intercontinental epidemics of group A Streptococcus.Propionibacterium freudenreichii Surface Protein SlpB Is Involved in Adhesion to Intestinal HT-29 Cells SpyAD, a moonlighting protein of group A Streptococcus contributing to bacterial division and host cell adhesion.Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.A novel cholesterol-insensitive mode of membrane binding promotes cytolysin-mediated translocation by Streptolysin O Four-component Staphylococcus aureus vaccine 4C-staph enhances Fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice.Non-invasive monitoring of Streptococcus pyogenes vaccine efficacy using biophotonic imaging Identification of a novel zinc metalloprotease through a global analysis of Clostridium difficile extracellular proteins Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery.The contribution of non-human primate models to the development of human vaccines The Human Pathogen Streptococcus pyogenes Releases Lipoproteins as Lipoprotein-rich Membrane Vesicles Vaccine candidate discovery for the next generation of malaria vaccines.Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children.Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models Reverse vaccinology in the 21st century: improvements over the original design.A review on recent developments in mass spectrometry instrumentation and quantitative tools advancing bacterial proteomics.Streptococcal toxins: role in pathogenesis and disease.Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.Development of Group A streptococcal vaccines: an unmet global health need.The role of structural proteomics in vaccine development: recent advances and future prospects.Streptococcus pyogenes adhesion and colonization.Vaccinology: The art of putting together the right ingredients Vaccination with Streptococcus pyogenes nuclease A stimulates a high antibody response but no protective immunity in a mouse model of infection.Progress in vaccine development.Towards developing a vaccine for rheumatic heart disease.Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence.Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of SpyCEP, a candidate antigen for a vaccine against Streptococcus pyogenes.From empiricism to rational design: a personal perspective of the evolution of vaccine development.Prevalent emm Types among Invasive GAS in Europe and North America since Year 2000.

P2860

Q26739210-077F9707-DC61-4AE4-A7AE-9CB5D4DB5D63 Q26777382-393A3745-6E7C-44B2-B3C1-7269724F4A24 Q27679389-B4077CAA-BB18-434C-916D-B4F85134295C Q28728698-7783E766-448A-474E-8E24-1BE06639022F Q30377731-1B9A2C9F-08BE-4217-8DFD-17606BD1C71C Q33774725-F33EAE91-70CF-4ED8-BAF9-4E77503BD951 Q33899739-66921909-2322-488A-8287-24071780B59A Q34037511-B4E2B67A-5253-4CFF-BA7F-6890CBB92DC0 Q34413457-5A1FB75B-D376-4195-89C1-17BCAEB7F8DF Q34422117-4BC673F0-01A1-4078-AE1D-A3BA8014DE99 Q34478033-1D1AFC60-5872-415E-8495-F9C94BD96072 Q35054131-5BF73156-45E7-4072-8AE3-42E518E28875 Q35058561-FA4EDDA9-785B-436E-8A3A-4BB120AFF823 Q35148587-987EF7F8-9196-4470-B9AE-51696EB88C9C Q35737990-F6CE7C15-0D45-414D-B1F4-3A817059D447 Q35926198-AE5C52F3-6CD6-4458-9FB0-99E26A9B0D65 Q36413834-0705B528-323B-459C-A01E-737D3C071BAF Q36616151-43C7E776-CBC5-4D6F-82EB-B74E7C2993FA Q36698378-4F91D7DB-598D-417A-A0DC-5A76317E812E Q37027300-4CDF9D1F-476E-403F-A885-ADDD9C1F57A4 Q38092843-966A258D-37BC-4BBB-BD67-339B994A8F4E Q38102548-0C128F80-81A3-47F4-B888-02650877094F Q38598360-885724D5-83CB-43F2-965D-9BDC16A8787D Q38612165-A3630512-5C1C-4A23-8C32-01AF1BC29853 Q38631048-E1294C97-8CD6-4AD8-B74D-6A3A445F7860 Q38682335-2CD04EBA-6DD4-41E9-918C-14372B350A0C Q38867821-4B576AF4-9DCF-4856-8B3C-84828B14155B Q38922448-6AA102C1-69F6-4153-BD11-C8C82B6B63AE Q40196934-9050F1C6-A868-42AC-8E3A-88575260391A Q41510529-E06C4600-2876-477B-8D87-08631E71F13A Q41928281-DF5D4389-04FF-4984-B5DA-97F36AC5654C Q42638233-BAD5DF30-5DED-4C10-B9FC-CAE47BB6D3B8 Q42651535-3C115A4B-D05E-463F-BF80-A6A387CF6679 Q47633699-1E7244D9-5E35-4A53-A30A-5B0C9C74208A Q54234537-6997082D-49CF-49CB-B586-15615E2A1756

P2860

Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

http://www.wikidata.org/entity/Q36208963

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Multi high-throughput approach ...... he Group A Streptococcus case.

@ast

Multi high-throughput approach ...... he Group A Streptococcus case.

@en

type

label

Multi high-throughput approach ...... he Group A Streptococcus case.

@ast

Multi high-throughput approach ...... he Group A Streptococcus case.

@en

prefLabel

Multi high-throughput approach ...... he Group A Streptococcus case.

@ast

Multi high-throughput approach ...... he Group A Streptococcus case.

@en

P1433

Q36208963-22FF0193-A4C1-40FA-B306-3F9669DDAD42

P1476

Q36208963-022766F3-889B-479C-9819-7B72D06551DA

P2093

Q36208963-0759BE20-C6F4-47A0-8166-F3471CB6F037

Q36208963-19EADC56-3FC1-4041-8659-AC860714B7A2

Q36208963-1F2BE1B4-C1A6-4DB1-B269-A5B1941689B1

Q36208963-1FFAFFD4-B0E3-4C9A-946D-80F8E303748D

Q36208963-43FE175B-C2D4-487A-9E6F-2CC42682940F

Q36208963-45C8D8DA-6922-4B7B-8E0F-3F14077ABBCF

Q36208963-45E096A6-97DF-4322-BA32-873D330E7BE0

Q36208963-48FBB9EC-F0AD-4A16-84AD-A8BCF848B381

Q36208963-7087A4B9-EABC-4736-B37F-4CE17F915B18

Q36208963-74491FC4-65AD-475F-BD12-29982C3924FF

P2860

Q36208963-137B2006-6BE7-4E79-9C89-0A05FDC3CD70

Q36208963-1573722C-5945-48C7-AE79-FD0F344C9F0F

Q36208963-1A3AC300-4BA2-4A83-93F6-6F916FB26F5D

Q36208963-24CD782A-DC65-40C9-86DF-1D6B43E7AF30

Q36208963-28F80F5B-93BF-45CF-BE3A-A07CBA184520

Q36208963-360D8306-736A-45B0-B22B-8427F3172ACE

Q36208963-39117A0A-4276-4A9D-8696-4F91392C5B99

Q36208963-41EFFFD9-267E-4188-A36B-0C55DCD2A9F7

Q36208963-493A4A01-AD8B-4F8D-91C8-F636A1C61580

Q36208963-4E1958CC-DECC-455E-8B5B-BB7A1C5FE6DD

P304

Q36208963-90B6108F-913A-4E3D-B862-22EB3B91BD00

P31

Q36208963-7D88BEBD-D644-4983-B252-88A8ABED752B

P356

Q36208963-90387E07-2C09-4E12-B89F-F7DE09291525

P433

Q36208963-177B42EC-31A0-447D-B805-461D625856DD

P478

Q36208963-8F2C3073-9B93-4CC4-A6F4-913840A2E95D

P50

Q36208963-03DD8389-37F1-47C6-9850-12ED1F3F72E2

Q36208963-67DE2C9F-75DB-4A39-963D-5F15CAB30E9F

Q36208963-A422D37F-6834-4787-A79F-085F282325D6

Q36208963-DDB345A6-E549-4975-9756-9245F63896B6

P577

Q36208963-E4917F89-CAD0-4186-87E3-07BAC20CAC4F

P698

Q36208963-84A555E3-6644-4976-884A-D0FEE0231514

P932

Q36208963-EEEB24D1-A413-41EF-A652-7CC22493BFA0

P356

MCP.M111.015693

P1433

Molecular & Cellular Proteomics

P1476

Multi high-throughput approach ...... the Group A Streptococcus case

@en

P2093

Andrea G O Manetti

http://www.w3.org/2001/XMLSchema#string

Emiliano Chiarot

http://www.w3.org/2001/XMLSchema#string

Erwin Swennen

http://www.w3.org/2001/XMLSchema#string

Fabiana Falugi

http://www.w3.org/2001/XMLSchema#string

Giovanna Tuscano

http://www.w3.org/2001/XMLSchema#string

Giuliano Bensi

http://www.w3.org/2001/XMLSchema#string

Immaculada Margarit

http://www.w3.org/2001/XMLSchema#string

Manuela Garibaldi

http://www.w3.org/2001/XMLSchema#string

Maria Scarselli

http://www.w3.org/2001/XMLSchema#string

Marilena Gallotta

http://www.w3.org/2001/XMLSchema#string

P2860

Elongation factor Tu and E1 beta subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae

Pathogenesis of group A streptococcal infections

Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse.

Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens.

Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization.

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes

Persistence of type-specific antibodies in man following infection with group A streptococci

Current knowledge of type-specific M antigens of group A streptococci.

P304

M111.015693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/MCP.M111.015693

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22286755

http://www.w3.org/2001/XMLSchema#string

P932

3433891

http://www.w3.org/2001/XMLSchema#string